Wockhardt MD, chairman, board of directors and AGM

Mutual fund votes, meeting of 8 Aug 2025, 22 fund houses

• Adoption of: a) the Audited Standalone Financial Statement of the Company for the financial year ended March 31, 2025 together with the Reports of the Board of Directors and Auditors thereon and b) the Audited Consolidated Financial Statement of the Company for the financial year ended March 31, 2025 together with the Report of Auditors thereon.MoreLess

  22 for0 against
• Appointment of Director in place of Dr. Murtaza Khorakiwala(DIN: 00102650), who retires by rotation and, being eligible,offers himself for re-appointment.

  22 for0 against
• Ratification of remuneration of Rs. 3,35,000 (Rupees Three Lakh Thirty Five Thousands only) plus applicable taxes and reimbursement of out-of-pocket expenses payable to Kirit Mehta and Co., Cost Accoutants as Cost Auditors for the FinancialYear 2025-26.MoreLess

  22 for0 against
• Appointment of Mr. Virendra G. Bhatt, Practicing Company Secretary as Secretarial Auditor of the Company for a term of 5(five) years i.e. from the conclusion of 26th AGM till the conclusion of 31st AGM (to be held during calendar year 2030).MoreLess

  22 for0 against
• Approval of Material Related Party Transactions.

  ›Against Angel One Mutual Fund, Axis Mutual Fund, Bandhan Mutual Fund, Bank of India Mutual Fund, Capitalmind Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, ICICI Prudential Mutual Fund, Invesco Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, Nippon India Mutual Fund, SBI Mutual Fund, Trust Mutual Fund

  • Angel One Mutual FundGovernance Concern: Clubbed resolution. Transparency concern: Ambiguity regarding prior approval. Inadequate Description of Nature of Transactions. Ambiguity with regards to how these transactions are classified as in ordinary course of business . Past transactions cannot be ascertained due to the inadequate nature of transaction.
  • Axis Mutual FundThe proposed related party transactions between Wockhardt and WBA, Wockhardt and WBA subsidiaries and WBA with its subsidiaries have been clubbed in one resolution. The company should have brought the transactions with each entity separately for approval, to enable shareholders to cast their votes for each transaction specifically. Although transactions are operational in nature with no commercial impact on a consolidated level, they are enabling with transaction limits higher than the company's revenues. No disclosures have been made with respect to the extent of past transactions. We do not support this resolution on account of lack of clarity on the size and tenure of the proposed transactions. Furthermore, the board must also explain the holding structure of WBA and the rationale for promoters to own 9.6% of WBA.
  • Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual FundCompliant with law. Governance Concern: Clubbed resolution. Transparency concern: Ambiguity regarding prior approval. Inadequate Description of Nature of Transactions. Ambiguity w.r.t. how these transactions are classified as in ordinary course of business . Past transactions cannot be ascertained due to the inadequate nature of transaction.
  • Bank of India Mutual Fund, Trust Mutual FundThe proposed related party transactions between Wockhardt and WBA, Wockhardt and WBA subsidiaries and WBA with its subsidiaries have been clubbed in one resolution. The company should have brought the transactions with each entity separately for approval, to enable shareholders to cast their votes for each transaction specifically. Although transactions are operational in nature with no commercial impact on a consolidated level, they are enabling with transaction limits higher than the company’s revenues. No disclosures have been made with respect to the extent of past transactions. We do not support this resolution on account of lack of clarity on the size and tenure of the proposed transactions. Furthermore, the board must also explain the holding structure of WBA and the rationale for promoters to own 9.6% of WBA.
  • Capitalmind Mutual FundClubbed resolution. ambiguity about how these transactions are classified as OCOB. Inadequate description of nature of transactions and disclosures on past transactions with related parties
  • ICICI Prudential Mutual FundThe AMC has voted against the resolution as the AMC believes that the resolution is not supported by adequate disclosure and does not provide clarity with respect to the size of the transactions with Wockhardt Bio AG.
  • Invesco Mutual FundThe proposed related party transactions between Wockhardt and WBA, Wockhardt and WBA subsidiaries and WBA with its subsidiaries have been clubbed in one resolution. The company should have brought the transactions with each entity separately for approval, to enable shareholders to cast their votes for each transaction specifically. We do not support the resolution .Although transactions are operational in nature with no commercial impact on a consolidated level, they are enabling with transaction limits higher than the company’s revenues. No disclosures have been made with respect to the extent of past transactions. We do not support this resolution on account of lack of clarity on the size and tenure of the proposed transactions. Furthermore, the board must also explain the holding structure of WBA and the rationale for promoters to own 9.6% of WBA
  • Nippon India Mutual FundGovernance Concern: Clubbed resolution. Transparency concern: Ambiguity regarding prior approval. Inadequate Description of Nature of Transactions.
  • SBI Mutual FundApprove related party transactions between Wockhardt Limited (Wockhardt) and Wockhardt Bio AG, Switzerland (WBA) and WBA’s subsidiaries, and WBA and its own subsidiaries, upto USD 500 mn annually. Although transactions are operational in nature with no commercial impact on a consolidated level, they are enabling with transaction limits higher than the company’s revenues. No disclosures have been made with respect to the extent of past transactions. We do not support this resolution on account of lack of clarity on the size and tenure of the proposed transactions. Furthermore, the board must also explain the holding structure of WBA and the rationale for promoters to own 9.6% of WBA.

  8 for14 against
• Revision in remuneration payable to Dr. Huzaifa Khorakiwala(DIN: 02191870), Executive Director from Rs. 2.80 Crore toRs. 4 Crore per annum for a period of 3 (three) years commencing from March 31, 2026 to March 30, 2029 with authorityto the Board of Directors to further increase or vary the saidremuneration and components thereof, without further approval of the Members of the Company, upto an amount not exceeding Rs. 6 Crore per annum.MoreLess

  ›Against Axis Mutual Fund, Bank of India Mutual Fund, Invesco Mutual Fund, SBI Mutual Fund

  • Axis Mutual FundDr. Huzaifa Khorakiwala, Whole Time Director, is part of the promoter group. For FY25 his remuneration was Rs. 25.2 mn - entirely fixed and revised remuneration is estimated at Rs. 41.5 mn with an outer limit of Rs. 61.4 mn. We note during FY25, the company's business has improved significantly , this is reflected in growth and margin expansion of EBITDA, a strengthened balance sheet - a result of successful capital raises and a pipeline of high margin products that is expect to drive future growth. While we acknowledge the positive changes, to support the increase in remuneration there must be consistent and ongoing improvement in both its operational and financial health. Overall promoter compensation at over Rs. 110 mn is high for the size of profits. Therefore, we do not support the resolution. We raise concerns that Dr. Habil Khorakiwala, promoter, and father of Dr. Huzaifa Khorakiwala, is a member of the Nomination and Remuneration Committee. This creates a potential conflict of interest.
  • Bank of India Mutual FundDr. Huzaifa Khorakiwala, Whole Time Director, is part of the promoter group. For FY25 his remuneration was Rs. 25.2 mn - entirely fixed and revised remuneration is estimated at Rs. 41.5 mn with an outer limit of Rs. 61.4 mn. We note during FY25, the company’s business has improved significantly , this is reflected in growth and margin expansion of EBITDA, a strengthened balance sheet – a result of successful capital raises and a pipeline of high margin products that is expect to drive future growth. While we acknowledge the positive changes, to support the increase in remuneration there must be consistent and ongoing improvement in both its operational and financial health. Overall promoter compensation at over Rs. 110 mn is high for the size of profits. Therefore, we do not support the resolution. We raise concerns that Dr. Habil Khorakiwala, promoter, and father of Dr. Huzaifa Khorakiwala, is a member of the Nomination and Remuneration Committee. This creates a potential conflict of interest.
  • Invesco Mutual FundDr. Huzaifa Khorakiwala, Whole Time Director, is part of the promoter group. For FY25 his remuneration was Rs. 25.2 mn - entirely fixed and revised remuneration is estimated at Rs. 41.5 mn with an outer limit of Rs. 61.4 mn. We note during FY25, the company’s business has improved significantly , this is reflected in growth and margin expansion of EBITDA, a strengthened balance sheet – a result of successful capital raises and a pipeline of high margin products that is expect to drive future growth. While we acknowledge the positive changes, to support the increase in remuneration there must be consistent and ongoing improvement in both its operational and financial health. Overall promoter compensation at over Rs. 110 mn is high for the size of profits. Therefore, we do not support the resolution. We raise concerns that Dr. Habil Khorakiwala, promoter, and father of Dr. Huzaifa Khorakiwala, is a member of the Nomination and Remuneration Committee. This creates a potential conflict of interest. We do not support the resolution .
  • SBI Mutual FundDr. Huzaifa Khorakiwala, Whole Time Director, is part of the promoter group. For FY25 his remuneration was Rs. 25.2 mn - entirely fixed and revised remuneration is estimated at Rs. 41.5 mn with an outer limit of Rs. 61.4 mn. We note during FY25, the company’s business has improved significantly , this is reflected in growth and margin expansion of EBITDA, a strengthened balance sheet – a result of successful capital raises and a pipeline of high margin products that is expect to drive future growth. While we acknowledge the positive changes, to support the increase in remuneration there must be consistent and ongoing improvement in both its operational and financial health. Overall promoter compensation at over Rs.110 mn is high for the size of profits. We do not support the resolution.

  18 for4 against
• Revision in remuneration payable to Dr. Murtaza Khorakiwala (DIN: 00102650), Managing Director from Rs. 2.80 Crore toRs. 4 Crore per annum for a period of 3 (three) years commencing from March 31, 2026 to March 30, 2029 with authorityto the Board of Directors to further increase or vary the saidremuneration and components thereof, without further approval of the Members of the Company, upto an amount not exceeding Rs. 6 Crore per annum.MoreLess

  ›Against Axis Mutual Fund, Bank of India Mutual Fund, Invesco Mutual Fund, SBI Mutual Fund

  • Axis Mutual FundDr. Murtaza Khorakiwala, Managing Director, is part of the promoter group. For FY25 his remuneration was Rs. 25.2 mn - entirely fixed and revised remuneration is estimated at Rs. 41.5 mn with an outer limit of Rs. 61.4 mn. We note during FY25, the company's business has improved significantly , this is reflected in growth and margin expansion of EBITDA, a strengthened balance sheet - a result of successful capital raises and a pipeline of high margin products that is expect to drive future growth. While we acknowledge the positive changes, to support the increase in remuneration there must be consistent and ongoing improvement in both its operational and financial health. Overall promoter compensation at over Rs. 110 mn is high for the size of profits. Therefore, we do not support the resolution. We raise concerns that Dr. Habil Khorakiwala, promoter, and father of Dr. Huzaifa Khorakiwala, is a member of the Nomination and Remuneration Committee. This creates a potential conflict of interest.
  • Bank of India Mutual FundDr. Murtaza Khorakiwala, Managing Director, is part of the promoter group. For FY25 his remuneration was Rs. 25.2 mn - entirely fixed and revised remuneration is estimated at Rs. 41.5 mn with an outer limit of Rs. 61.4 mn. We note during FY25, the company’s business has improved significantly , this is reflected in growth and margin expansion of EBITDA, a strengthened balance sheet – a result of successful capital raises and a pipeline of high margin products that is expect to drive future growth. While we acknowledge the positive changes, to support the increase in remuneration there must be consistent and ongoing improvement in both its operational and financial health. Overall promoter compensation at over Rs. 110 mn is high for the size of profits. Therefore, we do not support the resolution. We raise concerns that Dr. Habil Khorakiwala, promoter, and father of Dr. Huzaifa Khorakiwala, is a member of the Nomination and Remuneration Committee. This creates a potential conflict of interest.
  • Invesco Mutual FundDr. Murtaza Khorakiwala, Managing Director, is part of the promoter group. For FY25 his remuneration was Rs. 25.2 mn - entirely fixed and revised remuneration is estimated at Rs. 41.5 mn with an outer limit of Rs. 61.4 mn. We note during FY25, the company’s business has improved significantly , this is reflected in growth and margin expansion of EBITDA, a strengthened balance sheet – a result of successful capital raises and a pipeline of high margin products that is expect to drive future growth. While we acknowledge the positive changes, to support the increase in remuneration there must be consistent and ongoing improvement in both its operational and financial health. Overall promoter compensation at over Rs. 110 mn is high for the size of profits. Therefore, we do not support the resolution. We raise concerns that Dr. Habil Khorakiwala, promoter, and father of Dr. Huzaifa Khorakiwala, is a member of the Nomination and Remuneration Committee. This creates a potential conflict of interest. We do not support the resolution.
  • SBI Mutual FundDr. Murtaza Khorakiwala, Managing Director, is part of the promoter group. For FY25 his remuneration was Rs. 25.2 mn - entirely fixed and revised remuneration is estimated at Rs. 41.5 mn with an outer limit of Rs. 61.4 mn. We note during FY25, the company’s business has improved significantly , this is reflected in growth and margin expansion of EBITDA, a strengthened balance sheet – a result of successful capital raises and a pipeline of high margin products that is expect to drive future growth. While we acknowledge the positive changes, to support the increase in remuneration there must be consistent and ongoing improvement in both its operational and financial health. Overall promoter compensation at over Rs. 110 mn is high for the size of profits. We do not support the resolution.

  18 for4 against
• Re-appointment of Mr. Akhilesh Krishna Gupta as an Independent Director of the Company for a second term of 5 (five) years from August 29, 2025 to August 28, 2030, and continuation of his directorship notwithstanding his attaining the age of 75 years during the said term.MoreLess

  22 for0 against
• Approval for raising of additional capital by way of one or more public or private offerings including through a Qualified Institutions Placement ("QIP") to eligible investors through an issuance of Equity Shares or other eligible securities for an amount not exceeding Rs. 2,000 Crore.MoreLess

  ›Against Angel One Mutual Fund, Capitalmind Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, Nippon India Mutual Fund

  • Angel One Mutual Fund, Nippon India Mutual FundGovernance Concern: Potential for significant dilution and no clarity regarding the reasoning behind not opting for Rights Issue.
  • Capitalmind Mutual FundSignificant dilution and no clarity on reasoning behind not opting for Rights issue
  • Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual FundCompliant with law. Governance Concern: Potential for significant dilution and no clarity regarding the reasoning behind not opting for Rights Issue.

  15 for7 against

Mutual fund votes, meeting of 28 Jun 2024, 8 fund houses

• To receive, consider and adopt:na. the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2024 together with the Reports of the Board of Directors and the Auditors thereon; andnb. the Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2024 together with the Report of the Auditors thereon.MoreLess

  ›Against Groww Mutual Fund, Motilal Oswal Mutual Fund

  • Groww Mutual Fund, Motilal Oswal Mutual FundUnqualified financial statements except certain non-material remarks identified in CARO Report. Non-Compliant with S.136(1) of the Companies Act: Non-disclosure of the audited financial statements of all the subsidiaries on the website of the Company.

  6 for2 against
• To appoint a Director in place of Dr. Huzaifa Khorakiwala (DIN: 02191870), who retires from office by rotation and being eligible, offers himself for re-appointment.

  ›Against Invesco Mutual Fund

  • Invesco Mutual FundHuzaifa Khorakiwala, 52, Promoter and Whole-Time Director, has been on the board since June 2009. He attended all board meetings held in FY24 and retires by rotation. His reappointment is in line with statutory requirements. Nevertheless, we raise concern over the promoters’ ability to turn around the business, given that the company has been reporting losses for several years. We believe the company needs professional management.

  7 for1 against
• Appointment of M/s. M S K C & Associates, Chartered Accountants as Statutory Auditors of the Company and Fixation of Remuneration

  ›Against Groww Mutual Fund, Motilal Oswal Mutual Fund

  • Groww Mutual Fund, Motilal Oswal Mutual FundCompliant with law. Governance concern: Inadequate justification for the material change in the Audit remuneration.

  6 for2 against
• Ratification of remuneration payable to the Cost Auditors for the Financial Year 2024-25

  8 for0 against
• Approval of Material Related Party Transactions

  ›Against Groww Mutual Fund, ICICI Prudential Mutual Fund, Invesco Mutual Fund, Motilal Oswal Mutual Fund

  • Groww Mutual Fund, Motilal Oswal Mutual FundCompliant with law. Governance Concern: Clubbed resolution and inadequate disclosures for certain RPTs proposed.
  • ICICI Prudential Mutual FundThe AMC has voted against the resolution as the AMC believes that the resolution is not supported by adequate disclosure and does not provide clarity with respect to the size of the transactions with Wockhardt Bio AG.
  • Invesco Mutual FundThe resolutions between Wockhardt and its subsidiaries, and between the subsidiaries and the step-down subsidiaries, are enabling with transaction limits higher than the company’s revenues. The transactions with KHIPL is for financial support upto Rs. 15 bn, at rates that are similar to KHIPL’s cost of funds or GSec rates of similar tenure plus a spread not exceeding 1%. We do not support the resolution on account of lack of clarity on the size and tenure of the proposed transactions. Further, Wockhardt has demonstrated an ability to raise funds from the market, therefore the need to rely on promoter entities for financial support is unclear

  4 for4 against
• Re-appointment of Dr. Habil Khorakiwala (DIN: 00045608) as an Executive Chairman and Fixing of his Remuneration

  ›Against Groww Mutual Fund, ICICI Prudential Mutual Fund, Invesco Mutual Fund, Motilal Oswal Mutual Fund

  • Groww Mutual Fund, Motilal Oswal Mutual FundCompliant with Law. Governance Concern: Concentration of power due to combined position of Chairman and ED.
  • ICICI Prudential Mutual FundThe AMC has voted against the resolution as the AMC believes that the rationale for increase in remuneration of Dr Habil Khorakiwala by 37% remains unclear while the profitability of the company continues to remain depressed with the company making a net loss of Rs 466 crs in FY2024.
  • Invesco Mutual FundHabil Khorakiwala, 81, Promoter and Executive Chairperson has been on the board since 1999. Under the promoters’ leadership, the company’s performance over the past five years has remained depressed and profitability continues to remain under pressure. We raise concern over the promoters’ ability to turn around the business, given that the company has been reporting losses for several years. We believe the company needs professional management. Furthermore, Habil Khorakiwala has been a member of the Nomination and Remuneration Committee since 2014, which raises concerns over potential conflict of interest. For FY24, he was paid a remuneration of Rs. 36.5 mn, an increase of 26%, despite the company continuing to post a net loss. His proposed remuneration is capped at Rs. 50.0 mn. The past remuneration has not been linked to company performance and proposed remuneration is high for the size and performance of the business

  4 for4 against
• Appointment of Amb. Ahmad Javed (DIN: 08668304) as an Independent Director of the Company

  8 for0 against
• Approval for raising of additional capital by way of one or more public or private offerings including through a Qualified Institutions Placement (‘QIP’) to eligible investors through an issuance of Equity Shares or other eligible securities for an amount not exceeding ₹ 1,000 CroreMoreLess

  ›Against Groww Mutual Fund, Motilal Oswal Mutual Fund

  • Groww Mutual Fund, Motilal Oswal Mutual FundCompliant with Law. Governance concern: Excessive dilution and no specific justification which indicates urgent need of funds.

  6 for2 against

Mutual fund votes, meeting of 14 Aug 2023, 1 fund house

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

• Adoption of Audited Financial Statements:nTo receive, consider and adopt:na. the Audited Standalone Financial Statements of the Company for the Financial year ended March 31, 2023 togethernwith the Reports of the Board of Directors and the Auditors thereon; andnb. the Audited Consolidated Financial Statements of the Company for the Financial year ended March 31, 2023 togethernwith the Report of the Auditors thereon.MoreLess

  1 for0 against
• Appointment of Director retiring by rotation:n To appoint a Director in place of Ms. Zahabiya Khorakiwala (DIN: 00102689), who retires from office by rotation and, beingneligible, offers herself for re-appointmentMoreLess

  ›Against Motilal Oswal Mutual Fund

  • Motilal Oswal Mutual FundCompliant with Law. Governance concern: Ms. Zahabiya Khorakiwala is also Director on Board of a competitor Pharma Company RPG Life Sciences Ltd.

  0 for1 against
• Ratification of remuneration payable to the Cost Auditors for the Financial Year 2023-24

  1 for0 against
• Appointment of Ms. Amelia Fernandes as an Independent Director of the Company

  1 for0 against
• Approval for re-appointment of Dr. Huzaifa Khorakiwala (DIN: 02191870) as an Executive Director and Fixation ofnRemuneration

  1 for0 against
• Approval for re-appointment of Dr. Murtaza Khorakiwala (DIN: 00102650) as Managing Director and Fixation ofnRemuneration

  1 for0 against
• Approval of Material Related Party Transactions

  1 for0 against
• Approval for raising of additional capital by way of one or more public or private offerings including through a Qualified Institutions Placement (‘QIP’) to eligible investors through an issuance of Equity Shares or other eligible securities for an amount not exceeding ₹ 1,600 CroreMoreLess

  1 for0 against

Mutual fund votes, meeting of 12 Aug 2022, 3 fund houses

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

• 1 - Adoption of Audited Financial Statement:na) The Audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2022 together with the Reports of the Board of Directors and Auditors thereon; andnb) The Audited Consolidated Financial Statements of the Company for the Financial Year ended 31st March, 2022 together with the Report of Auditors thereon.MoreLess

  3 for0 against
• 2 - To appoint a Director in place of Dr. Murtaza Khorakiwala (DIN: 00102650), who retires from office by rotation and, being eligible, offers himself for re-appointment.n

  3 for0 against
• 3 - Ratification of remuneration payable to Cost Auditors for the Financial Year 2022-23n

  ›Against Nippon India Mutual Fund

  • Nippon India Mutual FundLow audit fees

  2 for1 against
• 4 - Approval for payment of remuneration to Dr. Habil Khorakiwala, Executive Chairman for the period of last 2(two) years of his current tenure i.e., commencing from 1st March, 2023 till 28th February, 2025nMoreLess

  ›Against Nippon India Mutual Fund

  • Nippon India Mutual FundHolding dual positions of Managing Director and chairperson

  2 for1 against
• 5 - Approval for raising of additional capital by way of one or more public or private offerings including through a Qualified Institutions Placement (‘QIP’) to eligible investors through an issuance of equity shares or other eligible securities for an amount not exceeding Rs. 1,600 croreMoreLess

  ›Against Nippon India Mutual Fund

  • Nippon India Mutual FundInsufficient information

  2 for1 against
• 6 - Approval of Related Party Transactions

  1 for0 against

Mutual fund votes, meeting of 2 Aug 2021, 4 fund houses

• Adoption of Audited Financial Statement:nTo consider and adopt:na. the Audited Financial Statement of the Company for the financial year ended 31st March, 2021 together with the Reports of the Board of Directors and Auditors thereon; andnb. the Audited Consolidated Financial Statement of the Company for the financial year ended 31st March, 2021 and the Report of Auditors thereon.nMoreLess

  4 for0 against
• Appointment of Director:nTo appoint a Director in place of Dr. Huzaifa Khorakiwala (DIN: 02191870), who retires by rotation and being eligible, offers himself for re-appointment.n

  ›Against Nippon India Mutual Fund

  • Nippon India Mutual FundHolds two full time positions

  3 for1 against
• Ratification of remuneration payable to Cost Auditors for the Financial Year 2021-22.

  4 for0 against
• Appointment of Mr. Akhilesh Gupta as an Independent Director of the Company

  4 for0 against
• Re-appointment of Mr. Vinesh Kumar Jairath as an Independent Director of the Company.

  4 for0 against
• Approval for continuation of Mr. Aman Mehta as an Independent Director upon his attainment of age of 75 years till the completion of his term.

  ›Against Nippon India Mutual Fund

  • Nippon India Mutual FundProlonged association with the company

  3 for1 against
• Approval for payment of remuneration to Dr. Huzaifa Khorakiwala, Executive Director of Rs. 2.40 crore for a period of 2 (two) years commencing from 31st March, 2022 till the expiry of his term of appointment i.e. 30th March, 2024.MoreLess

  ›Against Nippon India Mutual Fund

  • Nippon India Mutual FundHolds two full time positions

  3 for1 against
• Approval for payment of remuneration to Dr. Murtaza Khorakiwala, Managing Director of Rs. 2.40 crore for a period of 2 (two) years commencing from 31st March, 2022 till the expiry of his term of appointment i.e. 30th March, 2024.MoreLess

  ›Against Nippon India Mutual Fund

  • Nippon India Mutual FundRemuneration is high

  3 for1 against
• Approval for raising of additional capital by way of one or more public or private offerings including through a Qualified Institutions Placement (‘QIP’) to eligible investors through an issuance of equity shares or other eligible securities for an amount not exceeding Rs. 1,500 crore.MoreLess

  ›Against Nippon India Mutual Fund

  • Nippon India Mutual FundInsufficient Information

  3 for1 against

Mutual fund votes, meeting of 3 Aug 2020, 2 fund houses

• Adoption of a) Audited Financial Statement of the Company for the financial year ended 31st March, 2020 together with the Reports of the Board of Directors and Auditors thereon; b) Audited Consolidated Financial Statement of the Company for the financial year ended 31st March, 2020 and the Report of Auditors thereonMoreLess

  0 for0 against

  2 abstained

• Appointment of Ms. Zahabiya Khorakiwala (DIN: 00102689), who retires by rotation and being eligible, offer herself for re-appointment

  0 for0 against

  2 abstained

• Ratification of remuneration payable to Cost Auditors for the Financial Year 2020-21

  0 for0 against

  2 abstained

• Approval for raising of additional capital by way of one or more public or private offerings including through a Qualified Institutions Placement ('QIP') to eligible investors through an issuance of equity shares or other eligible securities for an amount not exceeding Rs. 1,500 crore.MoreLess

  0 for0 against

  2 abstained